U.S. Supreme Court Justice Antonin Scalia, FDA Commissioner Andrew C. von Eschenbach Among Featured Speakers at March 26-27, 2008, FDLI/FDA Meeting in Washington, D.C.
WASHINGTON, Jan. 9 /PRNewswire-USNewswire/ -- The Food and Drug Law Institute's 51st Annual Conference, co-sponsored with the Food and Drug Administration, will focus on the interrelationship between scientific and technological advances and food & drug law & regulation.
FDLI/FDA's March 26-27, 2008 meeting at the L'Enfant Plaza Hotel in Washington, D.C., will include a luncheon speech by U.S. Supreme Court Justice Antonin Scalia and a State of the FDA address by Commissioner Andrew C. von Eschenbach, M.D. Rep. John D. Dingell (D-Mich.) is also an invited featured speaker.
As noted in the recent FDA Science and Mission at Risk Report (http://backweb.fdli.org/pdf/FDAScience.pdf), scientific advances often pose significant policy issues and challenges for legal and regulatory systems. While government agencies are authorized to develop and implement policies that stimulate scientific advances for the benefit of public health, they are also mandated to ensure safety, effectiveness and affordability. The FDLI annual meeting, Scientific Revolution and Legal Evolution: Keeping Pace with Science & Policy Issues in Food and Drug Law, focuses on these dynamic tensions while informing attendees about the impact of recent wide-sweeping food and drug legislation.
Other featured speakers include:
J. Scott Ballenger, Partner, Latham & Watkins;
Brian J. Donato, Partner, Hyman, Phelps & McNamara;
Lillian J. Gill, Director, Office of Compliance, Centers for Devices and Radiological Health, FDA;
Jesse L. Goodman, M.D., Director, Center for Biologics Evaluation and Research, FDA;
Peter Barton Hutt, Partner, Covington & Burling;
Gerald F. Masoudi, Associate General Counsel, Food & Drug Division, Department of Health & Human Services;
Daniel Meron, General Counsel, Department of Health and Human Services;
Thomas Miller, Member, Managing Board, Siemens Medical Solutions;
Paula A. Monopoli, Professor, University of Maryland School of Law & Founding Director, Women, Leadership & Equality Program;
Lydia Parnes, Director, Office of Consumer Protection, Federal Trade Commission;
David Schmidt, President & CEO, International Food Information Council;
Barry M. Straube, M.D., Chief Medical Officer, Center for Medicare & Medicaid Services;
Daniel E. Troy, Partner, Sidley Austin;
Janet Woodcock, M.D., Deputy Commissioner and Chief Medical Officer, FDA; and
Julie Zawisza, Assistant Commissioner for Public Affairs, FDA.
For a complete list of speakers and agenda, visit http://www.fdli.org.
The Early Bird Rates, effective through Feb. 15, are:
Both One Day
$945 $795 FDLI Members
$1,270 $1,020 Non-members
$395 $345 Government (Non-FDA, including FDAAA members who
are not currently employed)
$670 $470 Academics, 501(c)(3) Non-Profits
$399 $199 Full Time Students (Special discount: $350 for a
group of 5 or more who register for both days)
To register for the conference, visit http://www.fdli.org or call (800)956-6923 or (202) 371-1420.
Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field. For more information, visit http://www.fdli.org
|SOURCE Food and Drug Law Institute|
Copyright©2008 PR Newswire.
All rights reserved